STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

KPTI Schedule 13G filing by Goldman Sachs Group

Goldman Sachs Group reported beneficial ownership of 991 shares, representing 5.1% of KARYOPHARM THERAPEUTICS INC in this filing.

FiledMay 12, 2026
Ownership dateMar 31, 2026
Reported shares991
Reported ownership5.1%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0
Shared voting power 991
Sole dispositive power 0
Shared dispositive power 991
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$8.92as of May 12, 2026
Latest tracked price$1.99as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
Goldman Sachs Group
CIK
CIK0000886982
Accession
0000886982-26-000235
Form
Schedule 13G
Open SEC filing View KPTI ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →